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Highlights 
1. The line between normal and pathological ageing is not well-defined 
2. Pathological and normal brain ageing share similar mechanisms and risks factors  
3. Nutrition holds promises as a preventive strategy against cognitive decline 
4. Important methodological challenges in clinical studies need to be addressed 
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Abstract  
As people age they become increasingly susceptible to chronic and extremely debilitating 
brain diseases. The precise cause of the neuronal degeneration underlying these disorders, and 
indeed normal brain ageing remains however elusive. Considering the limits of existing 
preventive methods, there is a desire to develop effective and safe strategies. Growing 
preclinical and clinical research in healthy individuals or at the early stage of cognitive 
decline has demonstrated the beneficial impact of nutrition on cognitive functions. The 
present review is the most recent in a series produced by the Nutrition and Mental 
Performance Task Force under the auspice of the International Life Sciences Institute Europe 
(ILSI Europe). The latest scientific advances specific to how dietary nutrients and non-
nutrient may affect cognitive ageing are presented. Furthermore, several key points related to 
mechanisms contributing to brain ageing, pathological conditions affecting brain function, 
and brain biomarkers are also discussed. Overall, findings are inconsistent and fragmented 
and more research is warranted to determine the underlying mechanisms and to establish 
dose-response relationships for optimal brain maintenance in different population subgroups. 
Such approaches are likely to provide the necessary evidence to develop research portfolios 
that will inform about new dietary recommendations on how to prevent cognitive decline. 
 
Keywords: Cognition; preventive diet; cognitive decline; neuroprotection; 
neuroinflammation; cognitive ageing. 
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1. Introduction  
The significant increase in average life expectancy is one of society’s great achievements 
which has been associated with a shift in the leading causes of illnesses from infectious to 
non-communicable diseases. It is well known that the percentage of populations categorized 
as elderly (e.g. 65 years and older) will increase dramatically in almost every country in the 
next few decades. By 2060, the elderly population will be expected to grow from 17.4% to 
nearly 30% worldwide (European Comission and Eurostat, 2012). At the same time, there is a 
wealth of disparate data related to how nutrients, non-nutrient, food components and whole 
diets may impact on cognitive health and ageing. Numerous epidemiological studies indicate 
that long-term intake of a Mediterranean diet (emphasizing amongst others fruits, vegetables, 
and olive oil) correlates with better cognition in aged populations (Feart et al., 2010; 
Scarmeas et al., 2009; van de Rest et al., 2015). Mechanistic investigations in vitro and in 
animal models have demonstrated that anti-inflammatory compounds in plants stimulate 
neurogenesis and protect neurons from noxious insults. However, such studies could not be 
replicated in humans (Stangl and Thuret, 2009) and treatments with ibuprofen, or foods, such 
as turmeric, although decrease pro-inflammation biomarkers only rarely show any pro-
cognition effects, at least in intervention trials (Lee et al., 2013; Townsend and Pratico, 2005). 
Due to the lack of highly sensitive cognitive test batteries and control for individual 
differences, diets and nutrients are not proven to robustly alleviate cognitive decline over 
short periods.  
In the past 10 years, high-calorie/low-dietary fibre diets and risk and incidence of diet-related 
diseases (i.e. Type 2 Diabetes Mellitus (T2DM) or cardiovascular disease (CVD)) have been 
associated with age-related cognitive decline (Beydoun et al., 2008; Loef and Walach, 2013; 
Nepal et al., 2014; Whitmer et al., 2005). Available data on beneficial effects of several 
ingredients or nutrients (e.g. dietary fibre, low-glycaemic carbohydrates, resveratrol and 
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docosahexaenoic acid (DHA)) suggest that their consumption may decrease glycaemic spikes 
or improve plasma cholesterol or triglycerides levels, thus having the potential to help prevent 
cognitive decline (Greenwood, 2003; Greenwood and Winocur, 2005). 
Randomized placebo-controlled trials (RCTs) are the gold standard to confirm the effect of a 
nutritional intervention on cognitive decline, maintenance or improvement. However, such 
trials may be impossible to conduct for some nutrients, where subtle effects are predicted to 
add up over decades and may be significantly influenced by individual differences in the rate 
of cognitive decline.  
Currently, there are no dietary recommendations or accepted health claims referring to age-
related cognition on the foodstuffs marketed. It may be expedient to weigh evidence from 
pilot, cohort, case control and animal studies, and evaluate these together, rather than taking 
into account only RCTs. Some nutrients may exhibit stronger effects in conjunction with 
others, and thus, one aim of this review is to weigh effects of nutrients in isolation, such as 
DHA taken as fish oil supplements, versus combinations of particular bioactives such as 
found in the Mediterranean diet. Although the present review is mostly focused on the role of 
nutrients in cognitive decline, it also offers some insights about different aspects related to the 
process of ageing. Thus, it highlights important considerations about normal and pathological 
ageing and its measurement through the use of biomarkers of cognitive status, as well as 
metabolic conditions that are considered as risk factors for cognitive decline. Therefore, the 
main goal of the present review is to provide the most recent evidence from human 
observational and intervention trials along with key mechanistic studies in cell and animal 
models, on the current state of knowledge on nutrition and healthy brain ageing. 
 
2. Normal and pathological decline in cognitive function  
 6 
 
Major aspects of human cognitive function are influenced by a variety of factors including 
genetics, lifestyle, nutrition, disease, trauma, medicines, as well as both normal and 
pathological ageing. The group led by Salthouse (Salthouse, 2010) has compiled a convincing 
body of evidence demonstrating that notable age-related decline in cognitive function occurs 
in healthy individuals starting from the late 20s and continuing throughout the adult lifespan. 
Some headline conclusions from this research are that such decline occurs in all individuals, 
concern a wide range of major aspects of cognitive function (i.e. not simply memory) and are 
marked in nature (e.g. up to 2 standard deviations). Such findings have now been widely 
replicated (Wesnes KA and T, 2000; Wesnes and Edgar, 2014) and an important message is 
that the same aspects of cognition which decline with ageing also decline (at a much greater 
rate) both in Mild Cognitive Impairment (MCI) and in the dementias (Wesnes and 
Lenderking, 2012). Despite this compelling evidence, there is little regulatory support for the 
development of medicines to treat such declines. It is proposed that this time-based 
deterioration to crucial aspects of mental ability in healthy individuals should receive the 
same aggressive treatments as other age-related declines (such as eyesight deterioration). 
Nevertheless, there was a temporary surge of interest in this area over 25 years ago when the 
National Institute of Mental Health (NIMH) workgroup defined operational criteria for age-
associated memory impairment (Crook TH, 1986). Then, over the next few years a variety of 
drugs were evaluated to treat this condition with some limited success (e.g. 
phosphatidylserine) (Crook et al., 1991). Criticism from some quarters that the 
pharmaceutical industry was creating a new condition simply to sell drugs to treat something 
which occurs in most individuals (O’Brien, 1999) led the industry to move away from this 
area and concentrate on pathological declines such as MCI, Alzheimer’s disease (AD) and 
other dementias (Wesnes KA and T, 2000). In fact, during the last 10 years the news for novel 
drugs to treat MCI and AD has been overwhelmingly negative. No novel treatment has been 
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approved for treating AD, despite a massive worldwide research effort which has been 
overshadowed by the failure of over a hundred putative treatments (Becker et al., 2008; 
Cummings et al., 2014; Mullard, 2012). This has led the field to move its focus to prodromal 
and even preclinical stages of dementia, stimulated by diagnostic criteria designed in 2007 to 
capture earlier stages based on early episodic memory loss alongside with biomarker evidence 
of disease pathology (Dubois et al., 2007). These criteria have been further refined (Albert et 
al., 2011; Dubois et al., 2010) and the goal posts broadened considerably with operational 
research criteria for preclinical AD (Sperling et al., 2011). Preclinical AD is particularly 
relevant as the trials would involve cognitively healthy elderly population. Regulatory 
authorities have become proactive. In fact, in a recent publication authored by Food and Drug 
Administration (FDA) officials the point was made that in preclinical AD trials, where 
functional impairment would be difficult to assess, it could be feasible to approve a drug 
through the FDA’s accelerated approval pathway on the basis of assessment of cognitive 
function alone (Kozauer and Katz, 2013). Therefore, a regulatory avenue has been opened in 
addition to new clinical criteria, and large trials in preclinical AD are already underway.  
 
3. Biomarkers of cognitive status 
AD is a slowly progressive neurodegenerative disorder with duration of several decades (Jack 
et al., 2011) showing 3 different phases; one preclinical and asymptomatic, a second one 
when cognitive performance starts to decline, and the last phase characterized by the typical 
memory-dominant dementia syndrome, which impairs everyday activities and patient 
autonomy (McKhann et al., 2011). In neuropsychiatric tradition, AD could only be diagnosed 
in a clinical setting if dementia was present, but a paradigm shift towards a more biologically 
defined AD diagnosis has been observed in recent years. The new National Institute on 
Ageing-Alzheimer’s Association (NIA-AA) guidelines conceptualize AD as a progressive 
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disorder including all possible stages from pre-symptomatic to severely demented (Jack et al., 
2011; McKhann, 2011). This way of thinking implies that tissue changes precede the onset of 
clinical signs by many years, and neuropathological lesions can be found in elderly 
individuals who presently do not have, and may not live long enough to ever suffer from 
cognitive impairment and associated disability (Giaccone et al., 2011). 
During the past 30 years, a large body of evidence has been accumulated indicating that a 
cascade of events related to the faulty production, degradation and clearance of amyloid-β 
protein (Aβ) lie at the heart of AD pathogenesis. Upstream events within this cascade include 
the overproduction of the amyloid-β precursor protein (AβPP) caused by rare mutations in the 
AβPP, PSEN1 or PSEN2 genes, malfunctioning of Aβ-degrading proteases and impaired 
clearance as a result of ineffective active or passive transport mechanisms (Jack et al., 2011). 
The imbalance between production and clearance results in excessive amounts of Aβ, which 
are believed to trigger a sequence of subsequent, i.e. downstream, pathological changes such 
as loss of synapses and neurons, impaired glucose utilisation, oxidative damage, brain 
metabolic reduction, tau hyperphosphorylation and associated neurofibrillary tangle 
formation, Aβ deposition in plaques and eventually neurotransmitter changes and widespread 
neurodegeneration. This complex cascade of pathological events continues throughout the 
course of AD, leading to an accumulation of structural and functional cerebral damages 
causing the typical clinical feature of disease (Jack et al., 2011; Jack et al., 2010). 
The hope for disease modification as well as technological advances in biomarker discovery 
fuel the search for biological indicators of the AD pathophysiological process, which can be 
used to identify neurodegeneration independently of its clinical manifestations (Hampel et al., 
2010). Ideally, such a biomarker, alone or in combination with other markers, would 
distinguish between individuals with and without AD pathology. Furthermore, 
pathophysiological markers may also offer the added benefit of directly assessing response to 
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treatment options that target core processes of AD pathogenesis. However, biomarker 
evidence of treatment efficacy should not replace clinical evidence of patient benefit. 
Currently available AD biomarkers can generally be grouped into two categories. The first 
category comprises markers that indicate the type of pathology present, including 
cerebrospinal fluid (CSF) levels of Aβ1-42, total tau (tTau) and phosphorylated tau (pTau)181 
(Blennow et al., 2010) and positron emission tomography (PET) tracers of fibrillar amyloid 
such as flutemetamol, florbetapir, florbetaben and Pittsburgh Compound B (Herholz and 
Ebmeier, 2011). The second category consists of markers that provide information on the 
topography of pathological changes, such as MRI and fluorodeoxyglucose PET (Dubois et al., 
2010). Published evidence consistently shows that these biomarkers, alone or in combination 
with psychometric test results, offer an added value for the diagnosis of the early clinical 
stages of AD. Novel biomarkers that are more closely related to the core pathophysiological 
processes of AD are currently in development (Perneczky et al., 2014) such as soluble forms 
of APP, which can be measured in CSF (Perneczky et al., 2011) and blood (Perneczky et al., 
2013). 
 
4. Metabolic and molecular mechanisms contributing to brain ageing 
4.1 Cardiometabolic risk factors 
The role of cardiometabolic health, including vascular stiffness and reactivity in cognitive 
health and decline are being increasingly recognized. In a 1-year longitudinal study in patients 
older than 80 years higher aortic stiffness was associated with more pronounced decline in 
cognitive function (Benetos et al., 2012), and microvascular function was significantly 
impaired in dementia patients as compared to controls (Khalil et al., 2007). Although, the line 
between normal and pathological ageing may not be well-defined, certain metabolic 
alterations such as obesity or Type 2 diabetes mellitus (T2DM) may account for an increased 
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risk of suffering age-related cognitive decline, especially in the elderly. The dramatic global 
increase in the incidence of obesity over the last 50 years is having a large effect on the 
incidence of many chronic diseases including T2DM and dementia. Indeed, more than half 
(52%) of the adult population in the 27 European Union (EU) member states are overweight 
(BMI= 25.0-29.9 kg/m
2) or obese (BMI ≥ 30.0 kg/m2) (Eurostat statistics database et al., 
2012) with an average EU obesity incidence of 17% in adults (Eurostat statistics database et 
al., 2012). An excess of adipose tissue and its associated co-morbidities in middle-age, has 
emerged as a significant risk factor for age-related cognitive decline. A 27-year US cohort 
which consisted of overweight and obese individuals (aged 40-45 years) showed an odds-ratio 
(OR) (95% confidence interval (CI) of dementia of 1.35 (1.14-1.60) and 1.74 (1.34-2.26), 
respectively, relative to normal weight individuals (Whitmer et al., 2005). Comparable effect 
sizes of 1.5-2.0 OR have been documented in more recent analyses, including a meta-analysis, 
which reported an attributed risk of 12% of total dementia and 21% of AD associated with 
obesity in a US population (Beydoun et al., 2008). Indeed, including midlife obesity in 
forecast models typically results in a 10-20% higher prevalence of dementia (Loef and 
Walach, 2013; Nepal et al., 2014) than the doubling of prevalence predicted by 2030 based 
only on ageing-related demographics (Alzheimer’s Disease International, 2009). 
Metabolic syndrome (MetS) and T2DM have comparable impacts on dementia risk and have 
been reported in overweight and obese individuals, respectively. For example, a relative risk 
of 1.20 (1.02-1.41; 95% CI) of cognitive impairment was evident in MetS subjects as 
compared to healthy controls (Yaffe et al., 2004). Furthermore, in a recent meta-analysis 
including 19 studies, subjects with diabetes presented higher risk for AD (relative risk 
(RR):1.46, 95% confidence interval (CI): 1.20-1.77), vascular dementia (RR: 2.48, 95% CI: 
2.08-2.96), any dementia (RR: 1.51, 95% CI: 1.31-1.74) and MCI (RR: 1.21, 95% CI: 1.02-
1.45) than those without (Cheng et al., 2012). Interestingly, these results also showed that 
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diabetes increases the risk for AD independently of APOE4 status, although subjects with 
both diabetes and APOE4 had the highest risk for AD (Cheng et al., 2012). 
A growing body of epidemiological evidence is also suggesting that metabolic syndrome 
(MetS) and its associated components (impaired glucose tolerance, abdominal or central 
obesity, hypertension, hypertriglyceridemia, and reduced high-density lipoprotein cholesterol) 
may be important in the development of age-related cognitive decline, mild cognitive 
impairment, vascular dementia, and AD (Frisardi et al., 2010; Panza et al., 2012b).  Although 
some understanding exists regarding the role of glucose and insulin within the central nervous 
system (CNS), the physiological and molecular basis of the contribution of obesity and its 
comorbidities to cognitive decline, along with causality and independence of associations are 
poorly understood (Freeman et al.,2014). Although some understanding exists regarding the 
role of glucose and insulin within the central nervous system (CNS), the physiological and 
molecular basis of the contribution of obesity and its comorbidities to cognitive decline, along 
with causality and independence of associations are poorly understood (Freeman et al., 2014), 
but are likely to include: a) impaired vascular function and brain perfusion (Benetos et al., 
2012; Elias et al., 2009; Khalil et al., 2007; Picano et al., 2014), b) low grade inflammation, 
including altered adipose tissue production of adipokines (Kiliaan et al., 2014; Song and Lee, 
2013), c) poor glucose tolerance and utilization (Lamport et al., 2009), and d) loss of insulin 
sensitivity independent of the impact on glucose metabolism (Calvo-Ochoa and Arias, 2015; 
De Felice, 2013; Park et al., 2000; Williamson et al., 2012). In this context, AD is currently 
proposed as an “insulin resistant brain state” (Craft et al., 2013). In addition, insulin in the 
CNS is largely derived from the periphery (pancreas) with some local insulin produced by the 
dentate gyrus (hippocampus) and olfactory system (Kuwabara et al., 2011). In neurons, 
insulin regulates energy metabolism, differentiation, growth, survival, synaptic plasticity and 
neurotransmission and promotes hippocampal long-term potentiation (LTP), learning and 
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memory (Bingham et al., 2002; Calvo-Ochoa and Arias, 2015; Kuwabara et al., 2011; 
Skeberdis et al., 2001). Therefore, a loss of insulin sensitivity would be predicted to 
negatively impact on these metabolic processes. 
Neuroinflammation has been associated with the risk of developing dementia and cognitive 
decline (McGeer and McGeer, 1999; Yaffe et al., 2003). In a longitudinal study, Yaffe and 
colleagues examined the association between MetS and cognitive change in elderly Latinos. 
Participants with MetS with high inflammation (median serum CRP level ≥3.2 mg/L) had 
significantly reduces cognitive function, measured by using the Modified Mini-Mental State 
Examination (3MS) than those without high inflammation. In this study, the individual 
components of MetS were also examined as predictors of cognitive change. The authors 
concluded that, in elderly Latinos, the composite measure of metabolic syndrome is a greater 
risk for cognitive decline than its individual components, with the possible exception of 
impaired glucose control and high blood pressure (Yaffe et al., 2007). 
Interestingly, Solfrizzi and colleagues concluded in a longitudinal Italian population-based 
sample, that MetS appeared to be a risk factor of progression to dementia in MCI patients. 
However, it is unknown how MetS could increase the risk of dementia in these patients 
(Solfrizzi et al., 2011). Unfortunately, in this study, the number of events of progression to 
dementia in MCI patients was not sufficient to allow the authors to analyse the effect of MetS 
on the risk of developing a subtype of dementia. 
  
4.2 Anaemia 
The role of anaemia on cognition is still controversial and the potential mechanisms by which 
anaemia could impact on cognitive decline are still not understood (Andro et al., 2013). The 
main hypothesis proposed, points to the role of the chronic low oxygenation of the aerobic 
cortical tissue, even more in the presence of compromised compensatory processes due to the 
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neurodegenerative or vascular pathology underlying MCI (Andro et al., 2013). Alternatively, 
anaemia has been suggested as a frequent complication of chronic kidney disease which leads 
to decreased erythropoietin levels that in turn may increase the risk of neurodegeneration 
(Andro et al., 2013).  
The number of studies investigating the relationship between anaemia or haemoglobin 
concentration and dementia or cognitive decline has increased in recent years. However, the 
results of these studies are inconsistent (Lucca et al., 2008). Conflicting results have been 
found in studies investigating the association between anaemia or haemoglobin concentration 
and dementia or AD or vascular dementia mainly due to not appropriately adjusted 
confounding factors or inaccurate methodology (Lucca et al., 2008). Consequently, larger 
size, prospective, more representative and methodologically robust studies are needed to 
establish the possible effect of mild anaemia on cognition in elderly persons. 
 
4.3 Oxidative stress  
The brain is a highly metabolically active tissue that relies on oxidative phosphorylation as a 
way for maintaining energy. The level of oxidative stress plays a pivotal role in brain 
functioning and growing evidence suggests a delicate balance between free radicals 
production and brain protection or damage (Chakrabarti et al., 2011). A moderate oxy-radical 
production by the mitochondria, reported as physiological level of oxidative stress, is known 
to up regulate the mitochondrial biogenesis program and brain antioxidant capacity, and to act 
in brain protection. By contrast, accumulation of oxidative damages is a key mechanism of 
the ageing process and a common feature of ageing brain. That, together with age-related 
mitochondria decay, causes alterations of cellular architecture within the brain, and raises the 
fact that uncontrolled free radical production is a major contributor to the loss of neuronal 
homeostasis and neurodegenerative diseases development (Wang et al., 2014).  
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4.4 Neuroinflammation  
It has been observed in animal models of AD and Parkinson Disease, that systemic 
inflammation generates an exacerbated immune response in the CNS through the local innate 
immune system. Then, the priming pattern triggered by activated microglia, can be influenced 
not only by the sequence of neurodegeneration but also by the systemic inflammation or other 
secondary stimuli. Priming makes the microglia susceptible to a secondary inflammatory 
stimulus, which can then trigger an exaggerated inflammatory response (Perry and Holmes, 
2014).(Perry and Holmes, 2014). Activated microglia has the capacity to synthesize a wide 
range of pro-inflammatory and anti-inflammatory cytokines and molecular mediators, which 
contribute to the systemic inflammatory milieu and to the progression of neurodegenerative 
disease (Perry, 2004; Perry et al., 2007). During neurodegenerative events, neural damage 
leads to a loss or down regulation of neural ligands that bind to inhibitory receptors on the 
microglia, resulting in a reduced microglia inhibition. Priming of macrophages has been 
widely studied in vitro following the exposure to IFN-ɣ and lipopolysaccharide (Schroder et 
al., 2006). Low doses of lipopolysaccharides are sufficient to trigger microglia activation and 
sickness behaviour in both humans and non-human primates (Brydon et al., 2008; Hannestad 
et al., 2012; Harrison et al., 2009). 
Nevertheless, other molecules expressed in the injured brain such as the colony-stimulating 
factor-1 (CSF-1) (Chapoval et al., 1998) and C-C motif chemokine 2 (CCL2) (Bhattacharyya 
et al., 2002; Rankine et al., 2006) can also prime microglia. Activation of CSF-1 receptor 
(CSF-1R) by CSF-1 and IL-34 (Greter et al., 2012; Wang et al., 2012) drive microglia 
proliferation (Gomez-Nicola et al., 2013), which is significantly important since the primed 
state and the increased number of microglia both contribute to the exaggerated response 
observed in the brain in neurodegenerative disorders. 
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In addition, mutations in CSF-1R also lead to important white matter damages associated with 
progressive dementia but the disease onset and severity strongly depend on the mutation 
(Nicholson et al., 2013). The effects of the mutation on white matter region along with the 
fact that microglia remains more in white matter than in grey matter, suggest that microglia 
may have an important role in myelin or axonal homeostasis.  
Ageing, as the main risk factor for AD development, occurs with a chronic, low-grade 
systemic upregulation of the proinflammatory T helper type 1 response and a relative decline 
in the anti-inflammatory T helper type 2 response (Franceschi et al., 2007). A study which 
examined brain samples from patients with mild or late-stage AD investigated the type of the 
inflammatory response (M1- or M2-like: CNS activated microglia corresponding to 
‘cytotoxic’ and ‘repair’ subpopulations of macrophages in other organs) and tried to find 
serum markers that were associated with these two phenotypes (Sudduth et al.). Noticeably, 
the M1-like state was associated with increased levels of CCL3 and the M2-like state with 
increased serum levels of IL-1 receptor antagonists.  
It is well known that in the ageing population, an increasing number of individuals have more 
than one systemic disease (Barnett et al., 2012), which indicates that systemic inflammation 
has a relevant importance as a risk factor for AD. The group of Perry et al. has demonstrated 
that systemic inflammation and acute infections are associated with an enhanced rate of 
cognitive decline (Holmes et al., 2009) and increased symptoms of sickness in AD patients 
(Holmes et al., 2011). 
Therefore, according to all these data, the monitoring and prompt treatment of systemic 
disease, inflammation and infection may delay neurodegenerative disease progression and 
improve quality of life (Perry and Holmes, 2014).  
 
4.5 AMPK signalling and autophagy 
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Although, the precise neurobiological origin of dementia remains controversial, systems 
medicine approaches integrating recent advances in molecular technologies with 
computational methods are able to address this complexity and to identify key molecular hubs 
relevant for neurodegenerative dementia. These approaches, supported by the fast growing 
knowledge of human interactome, offer a platform to systematically explore not only the 
molecular complexity of a particular disease but also the molecular relationships among 
apparently distinct diseases. The group of Caberlotto et al. (Caberlotto et al., 2013) applied 
these novel systems biology approaches not only to clarify the molecular basis of AD, but 
also to characterize the molecular alterations of the subgroup of neurodegenerative disorders 
with the shared core symptom of dementia. By convergent analysis of multi-dimensional 
datasets, their study on AD revealed a major role of metabolism and, predominantly, of AMP-
activated kinase (AMPK) as a central dis-regulated process in AD. AMPK is a core signalling 
pathway in cellular homeostasis and crucial regulator of energy metabolism. Through the 
examination of neurodegenerative dementias, they integrated not only the current knowledge 
on the specific diseases, but also the molecular targets of drugs for the treatment of dementia. 
This study underlined once more the role of AMPK signalling and autophagy, a self-
degradative process that is important for balancing sources of energy in response to nutrient 
stress, as the molecular basis of neurodegenerative dementia (Caberlotto and Nguyen, 2014). 
Similar results were obtained from the integrative analysis of AD and T2DM, two 
multifactorial diseases of ageing with marked common pathophysiological features, which 
confirmed the autophagy pathway as the molecular mechanism altered in both diseases 
(Caberlotto and Nguyen, 2015). 
 
5. Prevention of cognitive decline through nutritional and other lifestyle 
interventions 
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Preclinical and clinical studies provide valuable data regarding the effect of particular dietary 
patterns and/or specific nutrients on cognitive function. For example, deleterious dietary 
habits (overfeeding, high caloric/low dietary fibre diet or consumption of low antioxidant 
nutrients) and sedentary lifestyle, or emotional stress, have been reported as key 
environmental factors for oxidative stress and brain disorders (Martin et al., 2006; Mattson, 
2012). Insulin resistance (IR) which is found in overweight, MetS, and T2DM individuals is 
one of the leading causes of oxidative stress. Given the negative effects of IR, inflammation 
and oxidative stress in brain, several dietary components, acting as antioxidant, anti-
inflammatory and/or insulin action potentiating factors, could positively participate in a 
preventive nutritional strategy for healthy ageing of brain. It is therefore necessary to increase 
research on the benefits of nutrition and healthy eating habits in order to identify the best 
dietary recommendations in human population. These will enable the prevention or delay of 
diseases and disability and increase quality of life in the elderly (Roman-Viñas and Serra-
Majem, 2014). Among existing dietary patterns, adherence to a Mediterranean diet is 
associated with less cognitive decline, dementia, or AD (Cao et al., 2015; van de Rest et al., 
2015) and fits the notion of a healthy dietary pattern (Maillot et al., 2011). For example, a 
meta-analysis showed that greater adherence to a Mediterranean-style dietary pattern during 
older adulthood was associated with a lower risk of developing several different health 
outcomes such as CVD, neurodegenerative disorders, cancer and overall mortality (Sofi et al., 
2010). In general, the Mediterranean diet is characterized by a high intake of vegetables, 
fruits, cereals, nuts and olive oil (as the principal source of added fat), a moderate intake of 
fish and alcohol (mostly wine), and a low intake of dairy products, red meat and meat 
products (Bach-Faig et al., 2011). Higher adherence to a Mediterranean-style diet was 
associated with higher intakes of several antioxidant nutrients, and other food bioactives such 
as polyphenols, which are present in fruits, vegetables, cereals and beverages such as wine, 
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coffee and tea. Particularly, the role of coffee and caffeine consumption in later-life cognitive 
decline and dementia has been examined in a recent systematic reviewed by Panza and 
colleagues including 28 studies, which reported a potential correlation of moderate 
consumption of coffee or caffeine-rich beverages with a reduction in cognitive decline (Panza 
et al., 2015). Consistent with this, Santos and colleagues in their systematic review and meta-
analysis of caffeine and cognitive impairment/decline conducted in nine cohort and two case 
control studies reported a nonsignificant relative risk (RR) of 0.98 [95% Confidence Interval 
(CI): 0.87–1.11], with moderate heterogeneity (Santos et al., 2010). Although, there was a 
lack of a linear dose-response relationship and an association was not found in all cognitive 
domains investigated, most of reviewed population-based studies pointed to a neuroprotective 
effect of coffee or caffeine consumption against cognitive impairment and neurodegenerative 
disorders, with a stronger effect among women than men (Arab et al., 2013; Liu et al., 2016; 
Panza et al., 2015; Santos et al., 2010).  
On the other hand, contrasting findings also exist between alcohol consumption and reduced 
risk of age-related cognitive decline (Panza et al., 2012a). One recent meta-analysis from 
epidemiological longitudinal studies on older adults suggested that, light-to-moderate alcohol 
(usually wine) consumption was associated with a 38% reduced risk of incident overall 
dementia (Peters et al., 2008). In addition, another meta-analysis reviewed 15 prospective 
studies including older adults and revealed that light-to-moderate alcohol intake was 
correlated with a 25-28% reduction in risk of AD, vascular dementia, and overall dementia as 
compared to alcohol abstinence (Anstey et al., 2009). Finally, a more recent systematic review 
and meta-analysis, which reviewed 74 studies in older individuals, found that moderate intake 
of alcohol reduced cognitive impairment or dementia risk, whereas heavy drinking was 
associated with a trend toward a higher risk for cognitive impairment and dementia (Neafsey 
and Collins, 2011). Altogether these studies indicate that light to moderate alcohol 
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consumption may protect against AD and dementia. However, the importance of drinking 
patterns and specific beverages remain unknown (Ilomaki et al., 2015). 
 
5.1 Specific nutrient levels and age-related cognitive decline  
Examination of biochemical indicators of diet in subject populations at high risk for dementia 
can serve to develop an evidence base for distinct nutritional requirements for the prevention 
of cognitive decline. In addition, comprehensive assessment of nutritional status beyond 
single or few nutrients can provide insight into the interactive features between nutrients that 
may be relevant to translational efforts. Thus, these “nutrient biomarker patterns” can be 
related to risk for pathological, structural and metabolic changes that precede cognitive 
decline and provide insight into mechanism. 
One of the earliest structural changes in the brain that precedes cognitive decline is the 
accumulation of paraventricular and subcortical deep white matter hyperintensities (WMH). 
These WMH may indicate a breakdown of the blood-brain barrier via ischemic changes and 
demyelination of axons (Prins and Scheltens, 2015) and are a risk factor for cognitive decline. 
The CSF/plasma ratio of blood derived albumin is another indicator of BBB function. Here an 
increase in the CSF/plasma albumin ratio indicates BBB breakdown (Chen, 2011). The BBB 
impairment is prevalent in about 25% of autopsy confirmed AD cases and is associated with 
more rapid decline over time. Specific nutrient concentrations in the CSF appear to be 
influenced by BBB integrity and this loss of CNS concentration is associated with worse 
prognosis in AD cases (Bowman, 2012). Another study has demonstrated that BBB function 
is modifiable through vitamin therapies (Lehmann et al., 2003). Thus maintaining BBB health 
may be one target for nutritional therapies aimed at maintaining cognitive function. This area 
and underlying changes at the BBB that influence transport and concentration of nutrients in 
the brain remain an open area for research.  
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One report applied a data-driven approach to derive nutrient biomarker patterns (NBPs) in the 
Oregon Brain Ageing Study. The study included 104 subjects with a mean age of 87 years-old 
and free of dementia at baseline. Eight distinct NBPs were identified and examined in relation 
to domain specific cognitive function and MRI measures of brain ageing (Bowman et al., 
2012). The results were remarkable in the sense that it appeared that some NBPs were 
associated with global cognition and others mapped more to certain cognitive faculties only. 
This would suggest that certain nutrient combinations operate on general mechanisms in the 
brain while others are more discrete. For example, two NBPs were associated with more 
favourable cognitive and MRI measures: one vitamin profile (high plasma B vitamins, 
antioxidants C, and E and vitamins D) and another high in plasma ω-3 fatty acids. The 
vitamin profile explained a significant portion of variance in global cognitive function and 
particularly, attention, visuospatial and executive functions. It was also associated with less 
total brain atrophy, a phenomenon that can be driven by Alzheimer’s type pathology. The 
omega ω-3 pattern appeared more important to vascular aspects (WMH volume and executive 
functions known to be sensitive to WMH accumulation). A third pattern characterized by high 
trans-fat was associated with less favourable cognitive functions across several domains and 
more total brain atrophy. Memory function was best in those with higher plasma lutein and 
HDL cholesterol (Bowman et al., 2012). The NBPs altogether explained 17% of the total 
variation in global cognitive function and 37% of total variation in total brain volume. These 
data suggest that biochemical indicators of diet capture magnitudes of effect well beyond 
what we are accustomed to observing in nutrition research. One explanation is that the 
nutrient biomarker pattern analysis appreciates “synergistic” features, and another is that 
misclassification bias of nutritional exposure is reduced in comparison to more conventional 
methods subject measures of diet in older adults. In a longitudinal study of older adults at risk 
for dementia and followed over 4 years, plasma levels of the two long chain polyunsaturated 
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fatty acids EPA and DHA were associated with less executive function decline and that 
relationship appeared to be mediated by WMH burden (Bowman et al., 2013). These studies 
suggest that nutrient biomarker pattern analysis is a fruitful strategy for studying nutrition, 
metabolism and dementia. What and how nutrients influence the neurobiology that 
contributes to age-related cognitive decline warrants much more research. Combining human 
induced pluripotent stem cells (iPS) cells biology, molecular and nutritional neuro-
epidemiology and clinical trials is a way forward. 
 
5.2 Nutritional assessment for disease prevention 
The purpose of nutritional assessment is to well-characterize the dietary patterns of 
individuals, and to assess their exposure to nutrients and the hundreds of non-nutrients 
provided by the diet, for example phytochemicals, food additives, and food contaminants. 
Then, this information can provide scientific evidence for the role of dietary factors on human 
health and well-being. Other purposes of nutritional assessment are to identify population 
groups who do not have an adequate nutrition for disease prevention and to develop nutrition 
programs for at risk populations in order to monitor their impact. Nutritional assessment is 
still a huge challenge, due to the extraordinary heterogeneity and variability of food choices, 
and our limited knowledge of the composition of foods beyond the ~60 essential nutrients. 
Ideal methods of nutritional assessment should be accurate, sensitive and applicable to many 
populations. Currently, available methods fall into four categories: 1) anthropometric 
methods, 2) clinical examination, 3) questionnaires, and 4) biomarkers. Anthropometric 
methods such as body mass index (BMI) measurement have been considered as indicators of 
the adequacy of energy intake, but the correlation with diet quality is very questionable. 
Clinical examination has been used to diagnose severe vitamin or mineral deficiencies. 
However, this method is not appropriate for mild deficiencies. Today, dietary assessment is 
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often conducted using Food Frequency Questionnaires (FFQs), where subjects must 
remember their intake of 10 to 300 food items over the previous year. Multiple 24 h recalls 
and food records are more precise but more expensive and therefore, other new technologies 
have been developed. Now, web-based questionnaires are applied in large cohort studies, as in 
the French NutriNet-Santé cohort which includes over 200,000 subjects (Hercberg et al., 
2010). Smart phone applications also seem promising. Nevertheless, even with more 
technology, questionnaires have inherent limitations due to self-reporting (Maillot et al., 
2011; Roman-Viñas and Serra-Majem, 2014; Sofi et al., 2010) and are susceptible to recall 
bias. Even if statistical techniques have been developed to correct measurement errors, 
questionnaires, especially FFQs, are suspected to markedly attenuate associations existing 
between dietary factors and health outcomes (Bach-Faig et al., 2011). The last approach for 
nutritional assessment is the use of biomarkers, which are quantified through targeted 
analyses of biofluids or tissues (Arts and Hollman, 2005; Scalbert et al., 2005). Biomarkers 
are independent of all the errors associated with questionnaires. Today, only a limited number 
of validated biomarkers of food intake have been use in epidemiology (Arts and Hollman, 
2005; Scalbert et al., 2005), for example plasma vitamin C or carotenoids for fruit and 
vegetable intake, alkylresorcinols for whole grains, and urine methyl-histidine for meat. Some 
polyphenols have also been occasionally used as biomarkers of intake for their main dietary 
source (van Dam et al., 2013), for example resveratrol for red wine or hesperetin for orange 
(Cassidy et al., 2013). These biomarkers have been discovered using a hypothesis-driven 
approach which means that a specific compound of the food was previously known, its 
bioavailability was documented and then a reliable method of analysis could be developed. 
However, validated markers discovered with this approach do not cover the large diversity of 
food in the human diet, and many new biomarkers are still needed. 
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In the last decade, metabolomics has emerged as a data-driven approach for biomarker 
discovery. The concept of the food metabolome has been defined (Scalbert et al., 2014) which 
represents all the metabolites present in human tissues and biofluids that directly derive from 
the digestion and metabolism of food chemicals. The food metabolome is affected by both, 
the dietary habits and the metabolic capacity of individuals.As an example, a medium-term 
controlled intervention study was conducted to find biomarkers of citrus fruits intake (Pujos-
Guillot et al., 2013) where 12 volunteers consumed 500 mL/day of orange juice or control 
drink for one month, in a cross-over design. The urine metabolomes analysed by non-targeted 
high resolution mass spectrometry were compared at the end of the experimental period. 
Some expected candidates biomarkers of orange juice intake were identified such as the 
glucuronides of the citrus flavanones, hesperetin and naringenin but new candidates were also 
found, including some terpene metabolites as well as proline betaine, which seemed even 
more sensitive than the flavanone metabolites (Pujos-Guillot et al., 2013). Proline betaine has 
been validated in independent studies, quantified in a range of foods and was found almost 
exclusively in citrus fruits (Scalbert et al., 2014). This case-study example and many others 
now demonstrate that metabolomics is an efficient approach to discover new reliable 
biomarkers of food intake in a data-driven approach. In total, more than 145 candidate 
biomarkers have been proposed for about 20 foods through these food metabolome studies, 
and interestingly about 75% were phytochemical metabolites (Scalbert et al., 2014a). These 
candidate metabolites must be validated as it has been done for proline betaine. 
Since interventional studies for all the foods of the human diet are not feasible, the use of 
cohort samples to identify candidate intake biomarkers for a range of foods at the same time 
can be performed. The Phenotyping using Metabolomics for Nutritional Epidemiology 
(PhenoMeNEp) project (Rothwell et al., 2014) used the SU.VI.MAX2 cohort which is a well-
characterized cohort of French adults and identified the strongest discriminant of coffee intake 
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as Atractyligenine glucuronide, a phase II metabolite of a diterpene, which contributes to the 
bitter taste of roasted coffee and which has never been reported in significant amounts in any 
other food sources (Rothwell et al., 2014). Two others strong discriminants were alkaloids, 
the diketopiperazine cyclo (isoleucyl-prolyl) and trigonelline. The three biomarkers were 
classified as excellent biomarkers when their performance was assessed using receiver-
operating characteristic (ROC) curves test. Certainly, metabolomics-derived coffee 
biomarkers will be used in the coming years, in particular to study the impact of coffee on 
cognition. 
Therefore, profiling of urine or plasma metabolomes in interventions or cohorts studies is 
efficient to discover new candidate biomarkers of food intake with a data-driven approach. A 
large initiative, the FoodBAll project (http://foodmetabolome.org/) has recently been funded 
by the European Joint Programming Initiative Healthy Diet for Healthy Life, to identify a 
large range of new nutritional biomarkers using metabolomics and to develop a harmonized 
scheme for their validation. Beyond biomarker discovery, food metabolome profiling 
covering a wide range of bioactives and biomarkers of intake in biofluids may become a new 
method for nutritional assessment, once the current technical difficulties for rapid and 
complete profile annotation will be overcome.  
 
5.3 Micronutrients 
As reported by numerous studies in animals and humans, essential antioxidant trace elements 
such as Zinc (Zn), Selenium (Se)) and /or insulin sensitizers (Chromium (Cr), Zn) are deeply 
implicated in brain protection. Selenoproteins, i.e. Selenoprotein P and Glutathione 
peroxidase, protect brain cells against oxidative stress. A low Se status increases the risk of 
cognitive decline. The greater is the decrease in plasma Se, the higher is the probability of 
cognitive decline as indicated in the study of Akbaraly et al. (Akbaraly et al., 2007). A 
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potential preventive relevance for an optimal Se status can be therefore speculated to maintain 
a healthy brain [63]. However, there is an absence of consistent clinical evidence regarding 
whether Se supplementation is beneficial for the treatment of AD (Loef et al., 2011). 
Zn also acts positively on brain health by improving insulin sensitivity and reducing 
inflammation and oxidative stress. However, so far no benefits on ageing brain are reported 
after Zn supplementation in humans and even a potential neurotoxic effect of Zn 
accumulation has been observed in AD patients (Nuttall and Oteiza, 2014). 
Cr deficiency has resulted in insulin resistance and increased oxidative stress (Roussel et al., 
2007). Indeed, in insulin resistant states (T2DM and MetS), increased Cr intakes are 
associated with improved cognitive functions (Krikorian et al., 2010). 
 
5.4 Polyphenols and polyphenol-rich diets 
A number of studies have observed protective associations between dietary polyphenols and 
the prevention of age-related chronic diseases such as CVD, diabetes, cancers, osteoporosis 
and neurodegenerative diseases (Arts and Hollman, 2005; Scalbert et al., 2005; van Dam et 
al., 2013). The strongest evidence of health-protective properties is for CVDs (Cassidy et al., 
2013; Hooper et al., 2008; McCullough et al., 2012). However, the well-known biases and 
measurement errors of dietary assessment tools make the precision and accuracy of dietary 
intake estimations difficult, and therefore, the associations observed between polyphenols and 
health are compromised. As a result, it is still challenging to develop personalized diet-related 
recommendations for dietary polyphenol intake, and further research on the identification and 
validation of new nutritional biomarkers is warranted (Zamora-Ros et al., 2012). 
In the epidemiologic InCHIANTI study (Invecchiare in Chianti, ageing in the Chianti area), 
the group of Andres-Lacueva investigated the associations between total urinary polyphenols, 
as biomarkers of total dietary polyphenols (Zamora-Ros et al., 2011), and all-cause mortality 
 26 
 
over a 12-year period among older adult participants (Zamora-Ros et al., 2013). Recently, 
they also investigated the associations between total polyphenols and cognitive decline over a 
3-year follow-up in older participants free of dementia at baseline (Rabassa et al., 2015). In 
these studies, they observed that participants who consumed a diet rich in polyphenols (>600 
mg/d) reduced the risk of all-cause mortality and the risk of cognitive decline in global 
cognitive function (using the mini-mental state examination), and in attention (using the Trail 
Making Test A), by 30%, 47% and 48%, respectively. By contrast, they did not reduce the 
risk of decline on executive function measured with the Trail Making Test B, as compared to 
those who consumed diets low in polyphenols (<500 mg/d). However, no association was 
observed between total urinary resveratrol metabolites, a biomarker of red wine consumption, 
and all-cause mortality (Rabassa et al., 2015).  
In addition, research on ageing effects has revealed several signalling pathways which have 
been experimentally demonstrated to be involved in the regulation of the ageing process 
(Salminen and Kaarniranta, 2012). The central effects of these polyphenols, at the 
transcriptomic level confirmed the involvement of specific molecular component of the 
AMPK-autophagy systems also in neuronal and glial cells (unpublished data). The 
modulation of AMPK and autophagy could potentially prevent not only neurodegeneration, 
but also, in more general terms, it could promote healthy cognitive ageing. 
Cinnamon polyphenols also deserve a special attention since they have been reported to 
reverse in vitro Tau protein aggregation and break up Tau filaments (Peterson DW et al., 
2009). Interestingly, cinnamon added to the diet also counteracts the increase of amyloid 
precursor protein (APP) and Tau protein induced by a high fat/high fructose diet in the rat 
brain (Anderson et al., 2013).  
Polyphenols intake is associated with consumption of fruits such as grapes, apples, pears, 
cherries and various berries contain between 200 and 300 mg of polyphenols per 100 g of 
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fresh weight (Llorach et al., 2012). Moreover, a cup of tea or a large cup of coffee contains 
around 100 mg of polyphenols. Red wine, chocolate, legumes and nuts also contribute to the 
polyphenol intake. Recent development in analytical techniques and in metabolomics should 
allow the measurement of large sets of polyphenol metabolites as biomarkers of usual dietary 
polyphenol intake (Llorach et al., 2012). This will be essential if we are able, finally, to make 
dietary recommendations regarding polyphenols for improving the autonomy and quality of 
life in older people.  
 
5.5 Flavonoids  
Amongst polyphenols, the flavonoid subclass has been extensively studied. Given the wealth 
of available data for these phytochemicals, we decided to present those as a separate 
paragraph. Flavonoids, found in a variety of fruits, vegetables and beverages, have been 
recognized as promising agents capable of influencing different aspects of synaptic plasticity 
resulting in improvements in memory and learning in both animals and humans (Del Rio et 
al., 2013; Spencer, 2008; Williams and Spencer, 2012).  
Accumulating evidence suggests that certain dietary flavonoids might delay the onset and/or 
slow the progression of AD (Williams and Spencer, 2012), but the precise identity of the 
bioactive form(s) involved is unknown and critical information about bioavailability and 
metabolism has hindered progress in the field. Despite significant advances in our 
understanding of the biology of flavonoids over the past 15 years, they are still mistakenly 
regarded by many as acting simply as antioxidants. Yet, flavonoids are much more likely to 
combat neuronal dysfunction and toxicity by recruiting anti-apoptotic pro-survival signalling 
pathways, increasing antioxidant gene expression, and reducing Aβ pathology (Williams RJ et 
al., 2004; Williamson et al., 2012). There is, however, a lack of consensus as to the precise 
identities of the flavonoids capable of exerting these effects, partly because flavonoids have 
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notoriously poor bioavailability and are extensively metabolised in vivo, but also because 
most in vitro studies use concentrations that are at least 100 fold higher than those found 
following dietary administration. The group of Williams has started to address some of these 
limitations by adopting unbiased in vitro screening strategies using flavonoids at 
concentrations that are potentially achievable in humans to mimic more closely what occurs in 
vivo as a first step towards identifying possible dietary interventions for AD (Cox et al., 
2015). Using an APP-GAL4 gene reporter assay in primary rodent neurones to screen 
modulators of APP processing they identified a number of flavonoids that potently inhibit β-
secretase activity. Most notably, the flavanols ()-epicatechin (EC) and epigallocatechin 
reduced β-secretase activity and Aβ production at nanomolar concentrations and reductions 
in Aβ pathology were also observed following oral administration of EC to APP-PS1 mutant 
mice. 
Since EC is readily absorbed and circulates primarily as glucuronidated, sulfated, and O-
methylated forms in human plasma, the observed bioactivity is most likely to reside in an EC 
metabolite. Therefore, Williams’ hypothesis was that dietary EC, acting as a prodrug, or 
alternatively a synthetic EC analogue based on a metabolite, had the potential to be developed 
into a prophylactic dietary supplement for AD. The molecular mechanism underlying this 
reduction in Aβ production both in wild-type neurons and in a transgenic model of AD is not 
clear but Williams et al. presented evidence suggesting that EC inhibits the β-site amyloid 
precursor protein cleaving enzyme 1 (BACE1) (Cox et al., 2015).  
A large body of evidence has also emerged from human intervention studies demonstrating 
that the consumption of flavonoid-rich foods is associated with cognitive benefits (for a 
review see (Macready et al., 2010; Williams and Spencer, 2012)). The mechanisms by which 
flavonoids exert these actions on cognitive performance are being elaborated, with evidence 
suggesting that they may modulate the activation status of neuronal receptors, signalling 
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proteins and gene expression (Rendeiro et al., 2012; Rendeiro et al., 2013; Williams et al., 
2008). Although whether these effects are mediated directly (i.e. within the brain) or from the 
periphery is currently unknown.  
There is considerable evidence suggesting that neuronal activity during cognitive performance 
is tightly coupled to increases in regional blood flow, a process known as cerebrovascular 
coupling (Attwell et al., 2010). Such processes are primarily mediated by nitric oxide (NO) 
generated by the activation of both endothelial nitric oxide synthase (eNOS in endothelium) 
and neuronal nitric oxide synthase (nNOS in neurons) (Toda et al., 2009). In particular, NO 
derived from eNOS activation contributes to cerebral arterial dilatation, by migrating to 
vascular smooth cells and increasing blood flow at the blood-brain interface (Atochin and 
Huang, 2011). Furthermore, there is increasing evidence suggesting that the cerebrovascular 
response is also mediated by NO liberated from nNOS-containing neurons adjacent to intra-
cerebral arterioles and capillaries (Schroeter et al., 2006).  
There is substantial evidence which supports the beneficial effects of flavonoids, in particular 
flavanols (Schroeter et al., 2006; Schroeter et al., 2010) and anthocyanins (Rodriguez-Mateos 
et al., 2013) on peripheral vascular function and blood flow (measured using flow mediated 
dilatation). These effects are mediated by the actions of absorbed flavonoid metabolites on 
NO bioavailability, via their potential to activate eNOS (Schroeter et al., 2006) and/or inhibit 
NADPH oxidase activity (Rodriguez-Mateos et al., 2013). Such improvements in vascular 
function occur acutely e.g. flavanols (cocoa, tea; 1-3h) (Schroeter et al., 2006) and 
anthocyanins (blueberry; 1-2h and 5h+) (Rodriguez-Mateos et al., 2013), are in the same 
timeframe and show cognitive improvements using similar interventions type. Furthermore, 
flavonoid-induced improvements in spatial memory in animal models (Rendeiro et al., 2012; 
Williams et al., 2008) share similarities with those of exercise-induced alterations in synaptic 
plasticity in the brain (Bechara and Kelly, 2013; Cotman et al., 2007), as both involve the 
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activation of Akt/PKB and the increased expression of BDNF (Spencer, 2009).  Indeed, 
Akt/PKB activates both eNOS and nNOS, via increases in intracellular Ca
2+
 levels in 
endothelial and neuronal cells, respectively (Dimmeler et al., 1999; Rameau et al., 2007) and 
thus, that may represent a common path by which flavonoids and exercise facilitate cognitive 
improvements. The central role that NO plays in flavonoid-induced improvements in human 
cognition and cerebral blood flow has been explored by the use of NOS inhibitors, which 
block the conversion of L-arginine to L-citrulline and inhibit NO production (Iadecola et al., 
1994). Future studies should utilize L-arginine analogues such as nitro-L-arginine methyl 
ester, nitro-L-arginine, and L-N 
G
-mono-methyl-arginine (L-NMMA) to help provide 
information on the role of NO and blood flow in mediating cognitive activity of polyphenols. 
Use of L-NMMA in humans has been shown to result in a fall in cerebral blood flow 
(Shabeeh et al., 2013) without altering basal metabolic activity (Kelly et al., 1994). The use of 
NOS inhibitors in vivo has the potential to assess the contribution that NO plays in mediating 
increases in cerebral blood flow and hyperemic responses to cognitive activity in response to 
flavonoid intervention. Applying such an approach to polyphenol clinical trials will provide a 
clearer mechanistic understanding of how flavonoid intake acutely mediates cognition and 
how such transient blood flow alterations may underpin longer-term improvements in 
humans. 
Recent datasets indicate that high flavanol intake (495 mg) is associated with improvements 
in human executive function and episodic memory at 2 h post-consumption, compared to a 
low flavanol control (23 mg) (Lamport et al., 2015). Similar data following anthocyanin 
intake (755 mg; delivered and controlled as blueberry) indicate that cognitive improvements 
are manifested at 5 h post intake reaching significance already at 1 h (Lamport et al., 2015). 
The time-course of these cognitive effects, along with Spencer’s recent peripheral vascular 
function/blood flow data, using flow-mediated dilatation (FMD) (Rodriguez-Mateos et al., 
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2013) suggested that the modulation of peripheral blood flow and cerebrovascular blood 
perfusion by flavanol-rich foods may mediate acute improvements in cognition. In support of 
this hypothesis, recent pilot data indicate that flavanol intake (495 mg) is capable of 
increasing cerebral blood perfusion within select regions of the brain, as measured by arterial 
spin labelling (Lamport et al., 2015) in a timeframe consistent with both peripheral vascular 
and cognitive test performance. Further, a memory testing procedure known as pattern 
separation has recently been identified which has the potential to demonstrate therapeutic 
response in men to compounds which promote hippocampal neurogenesis (Bakker et al., 
2008; Yassa et al., 2011). A paper has just appeared demonstrating that one of such tests was 
able to identify positive effects of a high-flavanol cocoa preparation in elderly healthy 
volunteers (Brickman et al., 2014). In this study, improved cognitive function with the cocoa 
preparation was accompanied by functional magnetic resonance imageing (fMRI) evidence of 
enhanced activity in the dentate gyrus which is the hippocampal site responsible for 
neurogenesis. However, to date, no cause-effect relationship has been investigated between 
flavonoid intake, vascular function and cognitive performance. In addition, very little is 
known about the longer-term effects of flavonoids on cognitive function in humans, or 
whether such effects may be sustained in the absence of intake, despite there has been a 
wealth of animal data in support of potential longer term efficacy (Corona et al., 2013; 
Rendeiro et al., 2012; Rendeiro et al., 2013; Williams et al., 2008).  
Despite clear evidence regarding the acute vascular effects of flavonoids shown in humans 
(Macready et al., 2010) and medium-term changes in synaptic plasticity markers 
demonstrated in animal studies (Spencer, 2009), the basic mechanisms of action of flavonoids 
in humans remains unclear, due to a lack of precise causative/mechanistic data. Future work 
should strive to determine the mechanistic basis of flavonoids-induced improvements in 
cognitive function by investigating the degree to which peripheral- and cerebral blood flow 
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induced by flavonoids metabolites plays in determining improvements in human cognitive 
performance, in particular attention and episodic memory. 
 
5.6 Vitamins  
Among vitamins, high dietary intakes of tocopherols are associated with a reduced AD or 
dementia incidence (Mangialasche et al., 2011). However, interventional studies using 
Vitamin E supplementation failed to report positive effects on the risk of AD (Barnard et al., 
2014) for vitamin C, although there has been inconsistency among observational studies 
relating dietary intake of ascorbic acid to improved cognition, some results have favoured an 
important role for ascorbic acid in cognitive health. Therefore, further research focused on 
investigating the specific role of ascorbic acid in AD with special attention to the study design 
and methodologies, which represent an important study limitation, has been suggested to 
provide more conclusive data (Harrison et al., 2014).  
The mechanisms that support the relation between vitamins B and the brain are mostly related 
to homocysteine (Hcy) metabolism, a marker of vitamin B insufficiency. Hcy is catabolized 
through a remethylation cycle mediated by folate and vitamin B12, which provides methyl-
group for several metabolic steps (Levitt and Karlinsky, 1992). Clinical evidence has 
demonstrated a correlation between elevated plasma (Hcy) and the occurrence of AD and 
thus, hyperhomocysteinemia has been suggested as an important risk factor of AD (Obeid and 
Herrmann, 2006; Seshadri et al., 2002). Observational studies have reported that people with 
high blood concentrations of Hcy have elevated risk for vascular disease (Clarke et al., 1991) 
and AD (Clarke et al., 1998). These studies prompted randomized trials to assess whether 
vitamins B positively impacted on cognition, but their results have been mixed. In one of the 
most recent systematic reviews, 35 cohort studies with a total number of 14,235 individuals 
were identified (O'Leary et al., 2012). Twenty-one studies were of good quality of which only 
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7 showed a beneficial association. This association was more consistent in studies that 
included the newer and more specific markers of vitamin B12 status such as methylmalonic 
acid (MMA) and holotranscobalamin (holoTC). The most recent Alzheimer’s Disease 
International (ADI) report on nutrition and dementia included 4 additional studies that all 
showed a beneficial association of a higher vitamin B status with less cognitive decline 
(Alzheimer's Disease International, 2014). Even after including those more recent studies still 
the majority of observational studies did not show a beneficial association. A meta-analysis 
was performed on RCTs performed in individuals with or without cognitive impairment (Ford 
and Almeida, 2012). Nineteen RCTs were included and the overall conclusion was that no 
effect of vitamin B supplementation was observed on cognition. Similar findings were 
reported in an earlier Cochrane review (Malouf and Areosa Sastre, 2003), which concluded 
that 4 RCTs provided no evidence for improvement in people with cognitive impairment or 
dementia when treated with folic acid with or without vitamin B12 or B6. However, a later 
Cochrane update (Malouf and Grimley Evans, 2008), which included 8 studies concluded that 
there was some effect. For instance, a better response to cholinesterase treatment with B 
vitamins was observed in some studies including both people with AD and without dementia.  
After these reviews some additional RCT results were published (Douaud et al., 2013; 
Hankey et al., 2013; Walker et al., 2012) of which two RCTs showed an effect. Several 
observational studies have included brain MRI and all showed at least some beneficial 
associations (de Lau et al., 2009; Sachdev et al., 2002; Smith et al., 2010; Tangney et al., 
2011; Vogiatzoglou et al., 2008).  
Some other conflicting results have been released by the Folate after Coronary Intervention 
Trial (FACIT) (n=800) which reported that folic acid had a significant effect on memory 
(Durga et al., 2007). This study showed that people who were treated with folic acid and had 
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high levels of Hcy (which is a risk factor for dementia and heart disease) had better cognitive 
function over a 2-3 years period than those who were not treated.  
One recent RCT (VITACOG trial) including 168 MCI patients has been performed that 
included brain MRI as an outcome measure and showed that after 24 months of vitamin B 
supplementation patients showed a 30% slower rate of brain atrophy (Smith et al., 2010). 
Additionally, in the same study it was demonstrated that vitamin B supplementation was able 
to slow the cognitive and clinical decline in people with MCI, in particular in those with 
elevated Hcy levels (de Jager et al., 2012). Despite this, reliable evidence requires large trials, 
avoidance of bias and sub-group analysis and meta-analyses of such trials. A recent meta-
analysis by Clarke et al. (Clarke et al., 2014) included all B-vitamin trials assessing effects on 
cognitive function. It assessed the effects of B-vitamins on individual domains of cognitive 
function, global cognitive function and cognitive ageing. Dietary supplementation with 
vitamins B to lower Hcy levels had no significant effect on individual domains, global 
cognitive function or cognitive ageing. Overall, it was shown that vitamins B had no 
beneficial effect on either cognitive ageing (Clarke et al., 2014) or vascular disease (Clarke et 
al., 2010). 
Another vitamin that has been widely investigated is vitamin D. Currently a large proportion 
of populations are vitamin D deficient, and in particular the elderly (van der Wielen RPJ et al., 
1995). Some vitamin D receptors are located in the brain and many mechanisms that may 
support its role in the brain have been identified (Brouwer-Brolsma and de Groot, 2015). 
Regarding observational evidence, Balion et al. (Balion et al., 2012) identified 37 studies that 
could be included in his meta-analysis. There was a large heterogeneity, in particular in 
different cognitive tests that were used as an outcome measure. Results based on 8 studies 
using the MMSE showed that participants with 25-hydroxyvitamin D (25(OH)D) 
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concentrations >50 nmol/L had a higher MMSE score than those with concentrations <50 
nmol/L.  
 
5.7 ω-3 PUFAs 
Long-chain ω-3 PUFAs, EPA and DHA have been associated with decreased brain 
inflammation and preservation of the integrity and function of neuronal membranes (Janssen 
and Kiliaan, 2014).For example, DHA which is a key component of phospholipid cell 
membranes, may modulate the amyloid precursor protein (APP), thereby reducing formation 
and increasing clearance of -amyloid, the main component of AD plaques (Alzheimer's 
Disease International, 2014).  
Observational evidence has been focused on the association between fish long-chain ω-3 
PUFA intake or ω-3 PUFA status and cognitive functioning, cognitive decline or dementia. 
More than 30 studies have been performed and the vast majority of studies have showed 
beneficial associations (van de Rest et al., 2012). In the first Cochrane review on ω-3 PUFA 
trials that was published in 2006, no single RCT could be included (Lim et al., 2006). That 
review was updated in 2012 and at that time the first RCTs in non-demented elderly and with 
a study duration of at least 6 months were published. In total, three RCTs were included with 
a total of 3,536 participants. The conclusion was that ω-3 PUFA supplementation had no 
effect on cognitive functioning (Sydenham et al., 2012). In the same year Mazereeuw et al. 
(Mazereeuw et al., 2012) performed a meta-analysis and included cognitively impaired and 
demented individuals as well. They included 10 RCTs and did not see an overall benefit for 
immediate recall after ω-3 PUFA supplementation in healthy or demented elderly. However, 
they found an effect on the specific cognitive domains for immediate recall, attention and 
processing speed in cognitively impaired non-demented individuals.  
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The research field is currently advancing by not only the inclusion of batteries of cognitive 
tests as an outcome measure, but also including MRI techniques. Several observational 
studies including brain MRI have been performed and all have showed at least some 
beneficial associations (Conklin et al., 2007; Pottala et al., 2014; Samieri et al., 2012; Tan et 
al., 2012; Titova et al., 2013; Virtanen et al., 2008). Also, one RCT has been performed in 65 
healthy elderly and with a study duration of 26 weeks (Witte et al., 2013). In this study 
beneficial effects were found on executive functioning, on the MRI measures of gray matter 
atrophy, and on white matter microstructural integrity.  
 
5.8 Calorie restriction 
Diet including total intake, frequency, and content has emerged as an important 
environmental factor that can impact brain plasticity, including adult hippocampal 
neurogenesis (AHN) (Stangl and Thuret, 2009; Zainuddin MS, 2012). The level of AHN 
decreases with age and has been linked directly to cognition and mood (Murphy et al., 2014). 
In rodents, an increase of neurogenesis in the hippocampus is associated with improved 
learning/memory abilities, whereas a decrease is associated with symptoms of depression 
(Mateus-Pinheiro et al., 2013; Snyder et al., 2011). Therefore, modulation of AHN by diet 
emerges as a potential mechanism by which nutrition impacts on mental health (Murphy et 
al., 2014). Synapse formation is a key site in the initiation of the neurodegenerative process 
occurring during AD pathology, and then, calorie restriction (CR) may have significant 
effects on the disease pathology via modulation of AHN and synaptic plasticity (Maruszak et 
al., 2014). Wu et al. (Wu et al., 2008b) found that CR (30% for 4 months) in the transgenic 
mouse model of AD significantly attenuated ventricle enlargement, hippocampal atrophy, and 
caspase-3- activation. For example, the effect of CR, limiting the intake compared to baseline 
unrestricted or ad libitum consumption, together with maintained levels of vitamin, mineral, 
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or other essential biomolecules has appeared to increase AHN. Furthermore, CR seems to 
improve the resilience of synapses to metabolic and oxidative damage and modulates the 
structure and functional status of synapses (Mattson, 2012). Moreover, CR has demonstrated 
to induce the differential expression of genes of which 25% are involved in synaptic plasticity 
(Park and Prolla, 2005). Mice have showed improved working memory after long-term CR 
(Kuhla et al., 2013; Steinman et al., 2011). An increase in the expression of NMDA receptors, 
essential for LTP and synaptic plasticity, has been found in the hippocampus of 60% CR 
obese rats as compared to age-matched ad libitum fed animals (Yilmaz et al., 2011). Taken 
together, while still further research is warranted to elucidate the mechanisms by which some 
dietary factors induce brain plasticity, animal and supported epidemiological studies have 
demonstrated that multiple dietary regimens and components increase the levels of AHN, 
enhance brain plasticity and promote synaptic function in the context of ageing. 
 
5.9 Ketogenic diets 
Very-low-carbohydrate ketogenic diets (VLCKD) have been used for many decades 
especially after the 1970s when they became popular for weight loss (Atkins, 1972). But it 
was in the early 1920s when the importance of the use of these diets became relevant from the 
clinical point of view and were successfully used to treat many pathological conditions such 
as epilepsy (Hartman et al., 2007), diabetes (Dashti et al., 2006), CVD factors (Paoli et al., 
2011) and neurological diseases (Baranano and Hartman, 2008). The review by Paoli et al. 
(Paoli et al., 2013) considers possible mechanisms for the therapeutic actions of the ketogenic 
diet (KD) on weight reduction and different diseases such as CVD and diabetes. Although, the 
exact mechanisms of action of the KD are still poorly understood recently reports have 
suggested that ketone bodies (KB) act as neuroprotective agents by raising ATP levels, 
diminishing the production of reactive oxygen species in neurological tissues and enhancing 
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the regulation of synaptic function though mitochondrial biogenesis (Bough and Rho, 2007). 
Moreover, the stimulation of PUFAs synthesis by a KD has been demonstrated to regulate 
neuronal membrane excitability mediated by voltage-gated sodium channels (Huffman and 
Kossoff, 2006).  
However, new research concerning one of these diets, the MCT ketogenic diet, has recently 
demonstrated a compelling mechanism of action in seizure control (Chang et al., 2015). These 
studies show that a fatty acid provided in the diet, decanoic acid (10:0), reduces seizures 
induced in hippocampal slices of rodent. Using the whole cell patch clamp with rat 
hippocampal slices, decanoic acid reduced excitatory postsynaptic currents by 38.9±5.5% at 
52 µg/mL concentration and inhibited α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors, which are a target for antiepileptic drugs. This inhibitory mechanism 
is specific to defined chemical structures, is effective against multiple AMPA subunit 
compositions, and is enhanced during synaptic activation. These results define how the MCT 
diet provides a way of controlling seizures by the diet, without the need for the production of 
ketones or for pharmacological intervention (Chang et al., 2015; Chang et al., 2013).  
Given that patients with AD show a higher incidence of seizures (Palop and Mucke, 2009), 
KD may be a successful diet for its clinical treatment. Supporting evidence suggests that acute 
elevation of serum β-hydroxibutyrate (β-OHB) (one type of KB) through an oral dose of 
MCTs shows cognitive improvements in AD patients. A recent RCT in 20 patients (55-58 
years) diagnosed with probable AD (n=15) or MCI (n=5) showed that acute administration of 
MCTs (40 g), which led to elevate β-OHB, was positively correlated to improved cognitive 
function (Reger et al., 2004). Another clinical trial performed in 152 patients with mild to 
moderate AD (Henderson et al., 2009) compared the effect of Axona
®
, a medical food 
containing a formulation of MCTs, or placebo and found that cognitive scores remained 
stabilized in the Axona
®
 group, while the placebo groups presented a decline in cognition, but 
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only among Apoε4(-) subjects. Although, Axona® formulation has been reported to be well-
tolerated in normal elderly volunteers, the proposed cognitive effect is uncertain in non-
demented elderly people. Importantly, all these cognitive responses to increased energetic 
substrates were strongly dependent on APOE genotype (Craft et al., 2000).  
 
5.10 Multicomponent diets 
The important role of diets and healthy lifestyle in the prevention of vascular disease 
development is widely accepted. Already 30 years ago pioneering studies on Greenland 
Eskimos indicated that intake of ω-3 long chain polyunsaturated fatty acids (ω-3 LCPUFAs) 
from fish and wildfowl had protective effects against CVD (Bang et al., 1971; Bang et al., 
1980). More recently, the Mediterranean diet containing fish, olive oil and nuts as important 
lipid containing components, has been shown in several prospective worldwide studies to be 
inversely associated with CVD (Estruch et al., 2013) and to have a strong protective function 
against hypertension, obesity, and AD risks (Calton et al., 2014; Grosso et al., 2014; Koliaki 
and Katsilambros, 2013; Scarmeas et al., 2009). Moreover a recent thorough systematic 
review and meta-analysis suggests that a higher adherence to the Mediterranean diet may 
affect not only the risk of AD, but is also associated with a reduced risk of developing MCI 
and AD, and a reduced risk of progressing from MCI to AD (Singh et al., 2014; Solfrizzi and 
Panza, 2014).Dietary lipids are also starting to be highly recognized in nutrition thanks to 
their direct actions on synaptic function and cognitive processes (de Waal et al., 2014; 
Kamphuis and Scheltens, 2010; Shah, 2011; Shah et al., 2013; van Wijk et al., 2014; 
Wurtman, 2008). Contrarily, diets high in saturated fat are becoming notorious for reducing 
molecular substrates that support cognitive processing and increasing the risk of neurological 
dysfunction in both animals and humans (Gomez-Pinilla, 2008; Li et al., 2013; Wu et al., 
2008a). Dietary factors can affect multiple brain processes by regulating neurotransmitter 
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pathways, synaptic transmission, membrane fluidity and signal-transduction pathways. Recent 
data published by the group of Kiliaan et al. (Jansen et al., 2014; Wiesmann et al., 2013; Zerbi 
et al., 2014) and latest data in mice models for AD and vascular impairment, have shown that 
the treatment with multicomponent diets promotes neuroprotection by decreasing 
inflammation, restoring cerebral blood flow and volume, inhibiting neurodegeneration, and 
enhancing neural plasticity by increasing neurogenesis (Wiesmann et al., 2016). In particular, 
they (Zerbi et al., 2014) showed that a specific combination diet (Fortasyn
TM
) containing 
membrane precursors such as ω-3 fatty acids and uridine monophosphate plus cofactors for 
membrane synthesis was able to inhibit/reverse the early functional connectivity reduction 
and cerebral blood flow (CBF) impairment in mice (both parameters were apparent already 
before cognitive decline). 
Thus, diet may serve as preventive strategy at very early, non-symptomatic phases of AD, 
especially because there are no currently effective treatments for AD. Therefore, future 
research should focus on the early, asymptomatic phase of the disease especially on the 
(cardio) vascular risk factors like atherosclerosis, hypertension, obesity and T2DM being 
modifiable via changes in lifestyle factors such as diet. 
 
5.11 Exercise 
Gradual and progressive memory decline is often one of the earliest hallmarks in AD which 
can strongly influence the quality of life of an individual. Several lifestyle factors may 
interfere with the rate of cognitive decline in the elderly such as diet and physical activity. 
The Study of Elderly’s Memory impairment and Associated Risk factors (SEMAR) has been 
set up in Indonesia and included 719 participants (aged 52-99 years) from different ethnic 
backgrounds in rural and urban Java (Jakarta, Citengah and Yogyakarta) (unpublished data). 
These cohorts as well as other similar cohorts in China, Netherlands, UK and USA, have 
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recently been set up to investigate whether lifestyle factors in different ethnic/cultural cohorts 
were associated with a reduced risk of dementia (ongoing study) and found that the 
combination of exercise and eating fruit had a cumulative effect in reducing dementia risk in 
Indonesia people (unpublished data)  
Many observational studies (Clifford A, 2009; Hogervorst E et al., 2012) have showed a 
reduced risk of dementia in people who exercise. For instance, in Indonesia it was found that 
older people who engaged in sports had a halved risk of dementia (Hogervorst E et al., 2012), 
which was similar to data from the US and other countries (Barnes and Yaffe, 2011). 
However, several reviews have also showed that only 50% of the studies including an 
exercise intervention showed cognitive improvement in older people (Clifford A, 2009; 
Hogervorst E et al., 2012) which might be due to poor adherence to the program.  Similarly, 
the group of Hogervorst (Hogervorst E et al., 2012) found that resistance band (muscle 
strength) exercises 2-3 times/week for 20-30min improved memory function. In addition, 
exercise may be effective as a preventive activity as it can lower blood pressure and total 
cholesterol, can reduce abdominal fat and improve immune and lung function, as well as 
improve cardiovascular function, which improves cerebral blood flow. As discussed 
previously, all these factors may be implicated in dementia. Importantly, exercise can also 
directly promote outgrowth of nerve cells which allows better communication between brain 
cells, which is often reduced in dementia (Clifford A, 2009). Even in people who have already 
developed dementia, walking and muscle strengthening exercises are likely to have positive 
effects on cognitive abilities (Hogervorst E et al., 2012).  
In conclusion, risk factors for AD are similar to those for CVD (heart), such as high blood 
pressure, smoking, high cholesterol and obesity and need to be treated in midlife at the latest 
to reduce the risk of dementia later in life. A multi-disciplinary change in lifestyles 
(combining exercise with healthy diets) with a focus on midlife is the most important factor 
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for prevention of dementia. Therefore, changing the lifestyle to a healthier one which includes 
exercise and a healthy diet can reduce the risk for both heart disease and dementia. 
 
6. Methodological challenges in nutritional interventions on cognition  
Epidemiological studies have shown that a lower risk of dementia or cognitive decline is 
associated with diets relatively low in energy (Luchsinger et al., 2002) but rich in several key 
nutrients and food derived non-nutrient bioactives, including long-chain ω-3 PUFA (Cunnane 
et al., 2009; Dacks et al., 2013), vitamins B (Clarke, 2008), antioxidants such as vitamins C, E 
(Mangialasche et al., 2010) and carotenoids (Li et al., 2012), and polyphenols (Joseph et al., 
2009). However, most RCTs that have administered these dietary components as supplements 
have yielded disappointing results on cognition so far, (Barberger Gateau et al., 2013; Clarke 
et al., 2014; Sydenham et al., 2012). There are, however, some notable interest, particularly in 
the Memory Improvement with DHA Study (MIDAS) (Yurko-Mauro et al., 2010), the 
Souvenaid
® 
combination of nutrients in mild AD (Olde Rikkert et al., 2015; Scheltens et al., 
2010; Scheltens et al., 2012), and the Prevention with Mediterranean Diet (PREDIMED) 
study (Valls-Pedret et al., 2015). Thus, epidemiological data and these “success stories” from 
a limited number of RCTs, provide the justification and valuable methodological insight. In 
addition, they could be used in combination with the implementation of more robust ‘fit-for-
purpose’ RCTs to demonstrate the impact of diet on cognition in older persons. Such 
interventions should be carefully powered and of adequate duration (chosen based on 
physiological insights into likely changes in the primary outcome measures during the 
intervention period) in order to prevent false negative findings. Three further aspects should 
be considered: 1) improving inclusion criteria in RCTs, 2) optimizing the composition of the 
nutritional supplement or the diet to be evaluated, and 3) defining more sensitive primary and 
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secondary outcomes which are also important methodological considerations that will be 
discussed below. 
Identification of individuals at high risk of cognitive decline or dementia, who should be 
included in RCTs assessing the impact of nutrition, who are likely to be sensitive and gain 
most benefit from the intervention should be based on early markers of disease progression, 
low dietary intake or blood levels of selected dietary components of interest, or genetic 
characteristics. The natural history of the pathophysiology of AD spreads over decades during 
which Aβ accumulates in the brain before the first cognitive symptoms appear (Jack et al., 
2013; Jack Jr et al., 2010) raising the question of the optimal window for prevention or the 
progression from the preclinical, ‘at-risk’ phase to a clinical diagnosis of disease. It is 
virtually impossible to demonstrate the efficacy of primary prevention in regard to cognitive 
decline. Thus, the main target of RCTs should be the secondary prevention, at a very early 
stage of cognitive decline. The MIDAS included middle-aged adults (aged ˃55 years) with a 
subjective memory complaint and preserved general cognitive function but a logical memory 
baseline score lower than that of normal younger adults (Yurko-Mauro et al., 2010) to explore 
the effect of DHA consumption (900 mg/day) for 24 weeks. These individuals also had low 
regular fish consumption, less than 200 mg/day DHA. After completion of the trial, those 
receiving DHA, scored significantly higher on several tests of memory than the control group. 
The use of genetic variation as an inclusion/exclusion criteria could also be considered, since 
several epidemiological studies and at least one RCT have suggested that the benefit of 
supplementation with DHA on cognition could be limited to non-carriers of the ε4 allele of 
the APOE4 gene, the main genetic risk factor for AD (Barberger Gateau et al., 2011). 
Epidemiology also allows characterization of healthy diets providing optimal combinations of 
foods and nutrients that are associated with better cognitive performance (Alles et al., 2012), 
providing the rationale for RCTs using combinations of supplements rather than single 
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nutrients. The most famous example is the Mediterranean diet, which has been associated 
with lower risks of dementia or cognitive decline in several epidemiological studies, mostly in 
Europe and the US (Feart et al., 2010; Lourida et al., 2013; van de Rest et al., 2015). 
However, there is great heterogeneity in the definition of the “Mediterranean diet” between 
studies especially in non-Mediterranean countries. The PREDIMED NAVARRA RCT in 
Spain, demonstrated that randomized participants who followed a Mediterranean diet enriched 
with virgin olive oil or nuts scored significantly better than the control group following a low-
fat diet on a global cognitive score 6.5 years later (Valls-Pedret et al., 2015). Few RCTs have 
evaluated the impact of multivitamin supplements on cognition (Grima et al., 2012). For 
instance, Souvenaid
®
 which contains ω-3 PUFA (EPA and DHA), B-vitamins, a mixture of 
antioxidants, and uridine monophosphate (UMP), was formulated to improve synapse 
formation and function (Cansev et al., 2015; Wurtman et al., 2009). A 24-week RCT 
conducted in patients with mild AD showed that the group receiving Souvenaid
®
 scored 
significantly better than the placebo group on the memory domain of the neuropsychological 
test battery, the primary outcome (Scheltens et al., 2012). The study also showed 
improvement on measures of functional connectivity (Scheltens et al., 2012), functional brain 
network organization (de Waal et al., 2014), and sustained memory improvement until 48 
weeks in an open label extension study (Olde Rikkert et al., 2015). This was the second study 
in mild AD with this intervention and confirmed the results of a proof-of-concept study which 
showed improved memory performance after 12 weeks (Scheltens et al., 2010). As these 
studies were conducted in subjects with early AD, more research is needed to define the 
optimal combination and doses of nutrients that could contribute to delay cognitive decline in 
older persons without AD diagnosis.  
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In the case of EPA+DHA, vitamin D and B vitamins, although there is relatively consistent 
epidemiological evidence to exhibit their independent impacts on cognition, RCTs have 
generally failed to demonstrate any efficacy.  
Identification of relevant and sensitive biomarkers of disease progression, based on 
knowledge of the specific molecular and physiological targets of the intervention of interest, 
can optimize the choice of primary and secondary outcomes in RCTs. MRI and fMRI can 
provide evidence of the impact of nutrients on brain structure and function The rate of brain 
atrophy was the primary outcome of the Hcy and B vitamins in cognitive impairment 
(VITACOG) study (Smith et al., 2010) which found that vitamin B intake in the active 
treatment group was associated with 30% less brain atrophy per year than in those receiving 
the placebo. The effect on brain atrophy and cognitive function was mainly observed in those 
with higher baseline homocysteine levels, which were lowered by vitamin B treatment (de 
Jager et al., 2012; Smith et al., 2010). However, some RCTs have yielded discordant results 
regarding their impact on mechanisms of action and cognition. The concentration of F2-
isoprostane in CSF, a marker of oxidative stress (lipid peroxidation), has been proposed as a 
sensitive but not specific biomarker of age-related brain injury (Li et al., 2014). In an RCT, 78 
patients with mild to moderate AD were randomized to receive a high dose antioxidant 
mixture (800 IU/d vitamin E, 500 mg/d vitamin C, and 900 mg/day α-lipoic acid) or 400 mg/d 
Coenzyme Q, another antioxidant compound, or a placebo (Galasko et al., 2012). After 16 
weeks, those receiving the antioxidant mixture had significantly decreased F2-isoprostanes in 
CSF as expected, but an accelerated cognitive decline. Thus, biomarkers should always be 
used in combination with cognitive outcomes. 
This lack of positive results in RCTs may be due to too short trial duration, not appropriate 
target group, use of an inadequate dose, lack of efficacy of single nutrients and/or not 
sufficiently sensitive methodology to measure the outcomes. However, the identification of all 
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these limitations will allow a better performance of future intervention trials. In addition, there 
is still need for well-designed trials that: a) have long intervention periods (at least >1.5 year), 
b) target at risk groups (mild cognitively impaired or nutrient deficient subjects), c) use 
harmonized cognitive test batteries (de Jager et al., 2014), d) include biomarkers and/or 
imaging measures, e) use a multi-nutrient or food pattern approach or a multi-domain 
approach, and f) whose design is aligned with specific mechanisms. Findings from 
epidemiological studies can be used to design more efficient RCTs assessing the impact of 
combinations of nutrients in well-targeted individuals, using both biomarkers and cognitive 
assessment as outcomes (Table 1). 
 
7. Conclusion 
Decline in cognitive abilities with age occurs in healthy individuals throughout the adult 
lifespan. Moreover, the line between normal and pathological ageing is not well-defined as 
neurological diseases start years before any clinical symptoms arise. Several health conditions 
such as CVD, diabetes or obesity are closely related to cognition. Therefore, when identifying 
dietary approaches to promote healthy brain ageing a holistic approach should be considered 
including nutrition, exercise and lifestyle factors, which not only target the brain but also 
overall cardio-metabolic health (Fig.1).  
The mechanisms associated with normal ageing, including oxidative stress, 
neuroinflammation and vascular dysfunction are the same as those contributing to the 
development of neurological diseases. However, in these pathological conditions, the 
mechanisms contributing to ageing are exacerbated and triggered by different factors which 
might be genetic or environmental.   
Preclinical studies in animals have consistently demonstrated the positive impact of several 
dietary components on cognitive performance and epidemiological studies have showed 
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successful association of select dietary patterns with cognitive status. Particularly there is 
reasonable evidence that consuming Mediterranean-style diets protects against cognitive 
impairment. RCTs approaches have showed mixed results with intervention with single 
dietary components generally disappointing while some multi-nutrient/non-nutrient 
interventions have yielded more encouraging results. These observations are consistent with 
the results from epidemiological studies indicating that an adherence to dietary patterns, rather 
than adequate intake of single dietary components may be the most effective means of 
protecting against cognitive decline. A major objective of future research is to define the 
nutritional requirement for healthy cognitive ageing, and to translate these into effective 
dietary recommendations.  
RCTs are the gold standard to probe the efficacy of drugs but it may not be the same for 
dietary components. In terms of primary prevention, it is logistically difficult to establish the 
effect of nutrition on cognition through RCTs which would require participants follow up for 
potentially decades. In terms of secondary prevention, targeting individuals at high risk of 
cognitive decline and learning from epidemiology as suggested in the last section of this 
review should allow a relatively rapid impact on cognition to be established. 
Finally, it is the aim of this group to continue with the revision of the state of the art on 
nutrition for the ageing brain by organizing a follow-up workshop. In particular, mechanisms 
of ageing and their interaction with nutrients will be revisited, and new avenues and 
mechanisms of cognitive ageing that may be influenced by nutrition will be identified. 
  
 48 
 
Table 1. Contribution of epidemiology to design more efficient RCTs assessing the 
impact of nutrition on cognition 
 
What epidemiology tells us What RCTs should do 
 
Lower intake or blood levels of some 
nutrients are associated with higher risk 
of cognitive decline or dementia 
 
=>Target individuals with specific nutritional 
insufficiency, based on dietary or biological data  
 
Significant cognitive decline is a late 
event in neurodegenerative diseases  
 
=>Target at risk individuals with more sensitive 
neuropsychological tests and biomarkers  
 
Interaction between ω-3 PUFA status 
and APOE4  
 
=>Stratify RCTs according to APOE4 genotype 
and probably other single nucleotides 
polymorphisms (SNPs) 
 
Healthy diets are associated with lower 
risk of cognitive decline or AD  
 
=>Use dietary supplements providing similar 
combinations of nutrients  
 
AD is a multi-factorial disease whose 
natural history spreads over decades 
 
=> Use early and specific outcomes:  
-biomarkers of disease progression 
-biomarkers of mechanisms of action 
(oxidative stress, inflammation, insulin 
resistance, lipids… etc.) in combination with 
cognitive outcomes  
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Figure 1. Overview of links between lifestyle interventions on cognition and healthy 
brain function during ageing. 
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